Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of agomelatine on circadian rhythms in Major Depressive Disorder
2010-024191-25Phase 3Completed
- Sponsor
- Servier
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Servier. Primary endpoints: Circadian rhythm parameters, Depression severity and 1 more. Started Feb 2012; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-024191-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024191-25.